On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
FridaySep 02, 2022 9:15 am

B2B iGaming Leader Golden Matrix Group Inc. (NASDAQ: GMGI) To Enter B2C Market with Recent Permit Approval

GMGI acquired 80% stake in RKings social gaming platform that earned $32 million in revenue and $2.6 million in net income during fiscal 2021 Permit application for Mexico approved others to follow as more governments legalize online gambling Online gambling revenues expected to reach $153.6 billion by 2030 at CAGR of 11.7 percent from 2022 to 2030  Golden Matrix Group (NASDAQ: GMGI), an iGaming leader based in Las Vegas, develops, and owns online gaming IP, turnkey online casino solutions, and configurable, scalable white-label gaming platforms for international gaming operators. The company’s extensive portfolio of proprietary technology has made it a…

Continue Reading

ThursdaySep 01, 2022 9:45 am

GeoSolar Technologies Inc. Seeks to Drive Solar Power Adoption Within the United States

The recently passed Inflation Reduction Act of 2022 will extend the investment tax credit, providing residential solar users with a tax credit equivalent to 30% of the cost of equipment The tax credits will seek to incentivise the continued growth of the US solar energy sector Although new solar energy capacity accounted for half of the growth of electricity generation capability within the US in 1Q22, the nation’s cumulative solar energy capacity is sufficient to power a mere 18 million homes Through its revolutionary SmartGreen(TM) Home solution, GeoSolar Technologies will help household lower both, their carbon footprint as well as…

Continue Reading

ThursdaySep 01, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research

When CNS went public in 2019, the funds went primarily into pre-clinical preparation, trial design approval, and drug manufacturing for its potentially pivotal global clinical trial of Berubicin for recurrent glioblastoma multiforme (“GBM”) So far, CNS has received FDA Fast Track Designation on its Berubicin clinical study, inching the company closer to offering a viable solution to the millions of people dealing with GBM, a devastating malignant brain cancer It remains committed to pushing the envelope in terms of research and development of potential GBM treatment, as we ll as brain cancers in general, to offer a viable solution to…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217